Loading...
XNAS
AXSM
Market cap5.29bUSD
May 16, Last price  
107.53USD
1D
0.29%
1Q
-18.01%
Jan 2017
1,493.04%
IPO
1,085.56%
Name

Axsome Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
13.73
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.09%
Rev. gr., 5y
%
Revenues
386m
+42.53%
00000000050,037,106270,600,000385,693,000
Net income
-287m
L+20.05%
-2,166,630-6,000,562-10,559,579-27,201,653-28,943,392-30,965,464-69,686,841-105,388,720-134,943,391-197,766,477-239,238,000-287,216,000
CFO
-128m
L-11.49%
-1,631,065-4,596,394-7,438,991-21,281,304-26,471,652-30,053,701-46,375,059-78,456,569-108,225,764-116,510,798-145,080,000-128,410,000
Earnings
Aug 04, 2025

Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
URL
https://www.axsome.com/
IPO date
Nov 19, 2015
Employees
422
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
385,693
42.53%
270,600
440.80%
50,037
 
Cost of revenue
220,380
447,132
222,399
Unusual Expense (Income)
NOPBT
165,313
(176,532)
(172,362)
NOPBT Margin
42.86%
Operating Taxes
85
960
10,633
Tax Rate
0.05%
NOPAT
165,228
(177,492)
(182,994)
Net income
(287,216)
20.05%
(239,238)
20.97%
(197,766)
46.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
40,784
258,750
236,256
BB yield
-1.01%
-7.16%
-7.53%
Debt
Debt current
1,835
2,534
425
Long-term debt
200,523
193,407
94,684
Deferred revenue
Other long-term liabilities
91,680
73,300
31,100
Net debt
(112,995)
(190,252)
(105,734)
Cash flow
Cash from operating activities
(128,410)
(145,080)
(116,511)
CAPEX
(582)
(702)
Cash from investing activities
(270)
(582)
(53,702)
Cash from financing activities
57,840
331,013
284,582
FCF
167,463
(183,967)
(183,193)
Balance
Cash
315,353
386,193
200,842
Long term investments
Excess cash
296,068
372,663
198,340
Stockholders' equity
(1,122,782)
(835,566)
(596,328)
Invested Capital
1,463,011
1,287,482
831,668
ROIC
12.01%
ROCE
48.59%
EV
Common stock shares outstanding
47,914
45,425
40,656
Price
84.61
6.31%
79.59
3.19%
77.13
104.16%
Market cap
4,054,025
12.13%
3,615,393
15.29%
3,135,793
120.64%
EV
3,941,030
3,425,141
3,030,059
EBITDA
165,313
(169,698)
(166,797)
EV/EBITDA
23.84
Interest
6,569
6,453
7,335
Interest/NOPBT
3.97%